All In Biotech

Drug Trial Radar · NCT04829773

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

An Open-Label Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Apr 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jan 3, 2019

Primary completion

Mar 29, 2019

Study completion Mar 29, 2019

Sponsor

Lead sponsor
Clementia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Apr 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Study to evaluate the effect of food and the effect of swallowing capsule whole versus sprinkling on apple sauce on the pharmacokinetics (PK)/bioavailability of palovarotene, and evaluate the effect of palovarotene on the PK of the CYP3A4 substrate midazolam.

Conditions

  • Fibrodysplasia Ossificans Progressiva

Interventions

  • PalovaroteneDrug

    oral capsules

  • midazolamDrug

    oral syrup

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum (peak) observed plasma drug concentrationTime frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13.
  2. Time to reach maximum (peak) (t max) observed plasma concentration following drug administrationTime frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
  3. Area under the plasma concentration time (AUC 0-last) curve from time zero to the last quantifiable time point, calculated by linear-log trapezoidal summationTime frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
  4. Area under the plasma concentration time curve from time zero to infinity (AUC 0-infinity)Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
  5. Apparent terminal disposition rate constant/terminal rate constant yzTime frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
  6. Apparent terminal elimination half-life (t1/2)Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
  7. Apparent volume of distribution after oral administration (Vd/F)Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
  8. Apparent total clearance of the drug from plasma after oral administration (cLF)Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
  9. Area under the plasma concentration time curve from time zero to 24 hours only for DDI cohortTime frame: Days 1, 2, 15, 16
  10. The last concentration before the next study drug administration at steady state for DDI cohortTime frame: Days 1, 2, 15, 16
  11. Maximum (peak) observed plasma drug concentration at steady state for DDI cohortTime frame: Days 1, 2, 15, 16
  12. Time to reach maximum (peak) observed plasma concentration following drug administration at steady state for DDI cohortTime frame: Days 1, 2, 15, 16
  13. Minimum observed plasma concentration at steady state, taken as the lowest plasma concentration during dosing interval for DDI cohortTime frame: Days 1, 2, 15, 16
  14. Accumulation ratio for DDI cohortTime frame: Days 1, 2, 15, 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cambridge Ipsen US

    Cambridge, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.